Chronic Inflammatory Condition of the Male Genital Tract

Assistance Publique - Hôpitaux de Paris113 enrolled

Overview

Men following after proven and treated urethritis, looking for signs of chronic genital inflammatory syndrome with oxidative stress. This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial. Duration of study : one year

The presence of leucospermia in an chronic inflammatory genital tract syndrome leads to an oxidative stress and alterations in sperm parameters. Inflammation also affect the glands of the genital tract. This can eventually leads to male infertility, long after the initial infection. But 10% of men who seek treatment for infertility have such a leucospermia, while it is a potentially treatable cause. Main aim of this study: Search of development of an inflammatory genital tract syndrome in patients with urethritis proven and treated at 6 months after the end of treatment.This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial. Primary endpoint: Seminal elastase value to 6 months after the end of treatment. (500ng/ml or greater) Secondary objective: * Search for a genital inflammation in patients with urethritis proven and treated at 12 months after the end of treatment * Search for oxidative stress in patients with urethritis proven and treated at 6 and 12 months after the end of treatment * Study of the frequency of relapses infectious and / or passages at the stage of chronic infection after acute urethritis * Assessment of the parallel evolution of the quality of sperm in the two groups Progress of research. Time frame Search : * Duration of inclusions: 12 months * Duration of patient follow-up: 12 months for control group, 14 months at most for patients taking into account the duration of treatment for urethritis which is 4 to 6 weeks * Total duration of the study: 26 months Patients \& Methods: French monocentric, prospective trial. 300 subjects are planned to be included for 150 subjects in each group

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

113

Conditions

Urethritis

Interventions

Sperm sampleOTHER

Sperm sample

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria common to both groups: * Subjects aged 18 and over * Voluntary and signed informed consent Inclusion criteria specific to the group "patient": * Patients with clinical signs of urethritis / or * Patients treated for urethritis following the usual protocols in the month before inclusionand / or * Patients with positive chlamydial research, or Mycoplasma genitallium or Garderella vaginalis or gonorrhea in the sperm or first urinary stream; Inclusion criteria specific to the group "control": \- Patients with no urethritis or no history of urogenital infection Exclusion criteria common to both groups: * Subjects not wishing to participate in the study * Subjects that have not signed the informed consent * Those not affiliated to the social security system (or entitled beneficiary) * Immunodepressed or have an infection associated with HIV, HBV or HCV * Chronic systemic disease Exclusion criteria specific to the group "patient": \- Patients with no signs of urethritis Exclusion criteria specific to the group "control": \- Subjects with signs of urethritis

Locations (1)

Hospital Cochin

Paris, France

Outcomes

Primary Outcomes

Seminal elastase value

The dosage of elastase will be do 6 months after the end of treatment.

Time frame: 6 months after the end of treatment.

Secondary Outcomes

Seminal elastase value

The dosage of elastase will be do 12 months after the end of treatment.

Time frame: 12 months after the end of treatment.

Presence of markers of oxidative stress

Presence of markers objectifying the existence of oxidative stress resulting in cellular alterations: Determination of 8-hydroxydeoxyguanosine (8-OHdG) and AOPP (Advanced Oxidation Protein Products)

Time frame: 6 to 12 months after the end of treatment

Functional impairment of the glands of the reproductive tract

Presence of biochemical evidence indicating a functional impairment of the glands of the reproductive tract (markers of prostate, seminal vesicles, and epididymis to the seminal biochemistry)

Time frame: 6 to 12 months after the end of treatment

Signs reflecting the sperm function

Presence of signs reflecting the sperm function (vitality, mobility, analysis of motion parameters by Computer Assisted Semen Analyzer(CASA))

Time frame: 6 to 12 months after the end of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.